54 related articles for article (PubMed ID: 8376999)
1. Toxic and protective effects of L-dopa on mesencephalic cell cultures.
Mytilineou C; Han SK; Cohen G
J Neurochem; 1993 Oct; 61(4):1470-8. PubMed ID: 8376999
[TBL] [Abstract][Full Text] [Related]
2. Protective Effect of Resveratrol Combined with Levodopa Against Oxidative Damage in Dopaminergic Neurons.
Zhang Y; Guo H; Fu H
Cell Biochem Biophys; 2024 Apr; ():. PubMed ID: 38619644
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous Formation of Melanin from Dopamine in the Presence of Iron.
Hedges DM; Yorgason JT; Perez AW; Schilaty ND; Williams BM; Watt RK; Steffensen SC
Antioxidants (Basel); 2020 Dec; 9(12):. PubMed ID: 33339254
[TBL] [Abstract][Full Text] [Related]
4. Dopamine Pharmacodynamics: New Insights.
Lauretani F; Giallauria F; Testa C; Zinni C; Lorenzi B; Zucchini I; Salvi M; Napoli R; Maggio MG
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791331
[TBL] [Abstract][Full Text] [Related]
5. Ocular Penetrance and Safety of the Dopaminergic Prodrug Etilevodopa.
Gao Q; Ludwig CA; Smith SJ; Schachar IH
Transl Vis Sci Technol; 2021 Oct; 10(12):5. PubMed ID: 34609478
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Zheng CQ; Fan HX; Li XX; Li JJ; Sheng S; Zhang F
Front Immunol; 2021; 12():683577. PubMed ID: 34248967
[TBL] [Abstract][Full Text] [Related]
7. A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation.
Steele JR; Strange N; Rodgers KJ; Padula MP
Proteomes; 2021 May; 9(2):. PubMed ID: 34073856
[TBL] [Abstract][Full Text] [Related]
8. The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.
Li H; Yang P; Knight W; Guo Y; Perlmutter JS; Benzinger TLS; Morris JC; Xu J
J Neurochem; 2020 Jan; 152(2):235-251. PubMed ID: 31613384
[TBL] [Abstract][Full Text] [Related]
9. Maltodextrin modified liposomes for drug delivery through the blood-brain barrier.
Gurturk Z; Tezcaner A; Dalgic AD; Korkmaz S; Keskin D
Medchemcomm; 2017 Jun; 8(6):1337-1345. PubMed ID: 30108846
[TBL] [Abstract][Full Text] [Related]
10. Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?
Post MR; Lieberman OJ; Mosharov EV
Front Neurosci; 2018; 12():161. PubMed ID: 29593491
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
Zhang J; Tan LC
Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151
[TBL] [Abstract][Full Text] [Related]
12. Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.
Choi SJ; Panhelainen A; Schmitz Y; Larsen KE; Kanter E; Wu M; Sulzer D; Mosharov EV
J Biol Chem; 2015 Mar; 290(11):6799-809. PubMed ID: 25596531
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Colamartino M; Santoro M; Duranti G; Sabatini S; Ceci R; Testa A; Padua L; Cozzi R
Neurotox Res; 2015 Feb; 27(2):106-17. PubMed ID: 25355370
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells.
Peritore CS; Ho A; Yamamoto BK; Schaus SE
Neuroreport; 2012 Dec; 23(17):989-94. PubMed ID: 23114623
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: general features, effects of levodopa treatment and future directions.
Freire MA; Santos JR
Front Neuroanat; 2010 Nov; 4():146. PubMed ID: 21120063
[No Abstract] [Full Text] [Related]
17. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration.
Cadet JL; Jayanthi S; McCoy MT; Beauvais G; Cai NS
CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):526-38. PubMed ID: 20632973
[TBL] [Abstract][Full Text] [Related]
18. No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study.
Oli RG; Fazeli G; Kuhn W; Walitza S; Gerlach M; Stopper H
J Neural Transm (Vienna); 2010 Jun; 117(6):737-46. PubMed ID: 20401731
[TBL] [Abstract][Full Text] [Related]
19. When should levodopa therapy be initiated in patients with Parkinson's disease?
Halkias IA; Haq I; Huang Z; Fernandez HH
Drugs Aging; 2007; 24(4):261-73. PubMed ID: 17432922
[TBL] [Abstract][Full Text] [Related]
20. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.
Chan PL; Nutt JG; Holford NH
Pharm Res; 2007 Apr; 24(4):791-802. PubMed ID: 17308968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
